Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21821560 | 0.85 | MAP1LC3B (0.46) | ALDH1A1MAPTLMNAMAP1LC3BHTT | |
| SCHEMBL26530728 | 0.83 | MEN1 (0.49) | MAP1LC3BMEN1KMT2A | |
| SCHEMBL21821980 | 0.83 | MAPT (0.65) | ALDH1A1MAPTLMNAMAP1LC3BL3MBTL1 | |
| SCHEMBL21821591 | 0.82 | SLC18A3 (0.50) | ALDH1A1MAP1LC3BGAAMEN1KMT2A | |
| SCHEMBL21773995 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAMAP1LC3BHTT | |
| SCHEMBL21821703 | 0.82 | MEN1 (0.42) | ALDH1A1MAPTLMNAMAP1LC3BHTT | |
| SCHEMBL21821755 | 0.82 | MAP1LC3B (0.44) | ALDH1A1MAPTLMNAMAP1LC3BHTT | |
| SCHEMBL21773998 | 0.82 | KMT2A (0.47) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL24899431 | 0.81 | MAP1LC3B (0.55) | ALDH1A1MAPTLMNAMAP1LC3BL3MBTL1 | |
| SCHEMBL21821987 | 0.80 | CYP2C9 (0.42) | ALDH1A1KDM4ELMNAMAP1LC3BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069609-A1 | METHOD FOR COVALENT BOND MODIFYING MAMMALIAN ATG8 HOMOLOGUE | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-03-05 | — | — | US | disclosed |
| US-20200069609-A1 | METHOD FOR COVALENT BOND MODIFYING MAMMALIAN ATG8 HOMOLOGUE | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069609-A1 | METHOD FOR COVALENT BOND MODIFYING MAMMALIAN ATG8 HOMOLOGUE | ATG7, ATG4A, MLST8 | ALDH1A1 4094/4885KDM4E 1558/4885MAPT 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.